ToTheMOON
2021-12-01
Thirty days later than yesterday lol
Regeneron's COVID-19 antibody drug may be less effective against Omicron<blockquote>Regeneron 的 COVID-19 抗体药物对奥密克戎病毒的疗效可能较差</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603962112,"tweetId":"603962112","gmtCreate":1638353740423,"gmtModify":1638353741190,"author":{"id":3576212227172632,"idStr":"3576212227172632","authorId":3576212227172632,"authorIdStr":"3576212227172632","name":"ToTheMOON","avatar":"https://static.tigerbbs.com/7769f4b8d26aa1903d8784e79b05b4df","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":47,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Thirty days later than yesterday lol </p></body></html>","htmlText":"<html><head></head><body><p>Thirty days later than yesterday lol </p></body></html>","text":"Thirty days later than yesterday lol","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603962112","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","kind":"news","pubTimestamp":1638330314,"share":"https://www.laohunote.com/m/news/1101502249?lang=zh_CN&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron<blockquote>Regeneron 的 COVID-19 抗体药物对奥密克戎病毒的疗效可能较差</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p><p><blockquote>11月30日（路透社）-<a href=\"https://laohu8.com/S/REGN\">再生元制药</a>该公司周二表示，Inc. 的 COVID-19 抗体药物对奥密克戎病毒的疗效可能较差，这加剧了人们对 Moderna 高层对该公司疫苗提出类似担忧后对现有治疗方法疗效的担忧。</blockquote></p><p> Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p><p><blockquote>Moderna (MRNA.O) 首席执行官的言论再次引发人们对该变种可能会给新生的全球经济复苏带来压力的担忧，导致全球市场暴跌。</blockquote></p><p> Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p><p><blockquote>Regeneron (REGN.O) 表示，根据对 Omicron 个体突变的研究，“疫苗诱导的免疫和单克隆抗体传递的免疫的中和活性可能会降低”，并补充说，该分析包括其 COVID-19 抗体鸡尾酒 REGEN-COV。</blockquote></p><p> The company said it was doing further study to quantify the potential impact using the variant's genetic sequence.</p><p><blockquote>该公司表示，正在进行进一步的研究，以利用该变体的基因序列量化潜在影响。</blockquote></p><p> One of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p><p><blockquote>首席执行官伦·施莱弗 (Len Schleifer) 在接受 CNBC 采访时表示，治疗中使用的一种抗体可能会受到影响，而另一种抗体则不会受到影响。</blockquote></p><p> \"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p><p><blockquote>\"<a href=\"https://laohu8.com/S/JE\">刚刚</a>就像疫苗必须适应一样，我们可能必须不断适应我们的单克隆。”</blockquote></p><p> <a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p><p><blockquote><a href=\"https://laohu8.com/S/LLY\">礼来和</a>Co(LLY.N) 在一份电子邮件声明中告诉路透社，该公司也在努力了解其疗法对奥密克戎的中和活性。</blockquote></p><p> Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p><p><blockquote>再生元股价在早盘交易中下跌约 3%，礼来公司股价下跌 2.5%。</blockquote></p><p> Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p><p><blockquote>竞争对手 Vir Biotechnology Inc(VIR.O) 表示，基于奥密克戎序列，其抗体疗法 sotrovimab 可能会保持对该变异体的效力。</blockquote></p><p> The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p><p><blockquote>它补充说，该公司“正在紧急努力在实验室确认这一点”。</blockquote></p><p> Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p><p><blockquote>吉利德公司 (GILD.O) 表示，相信其静脉注射疗法瑞德西韦（目前唯一获批用于治疗 COVID-19 的抗病毒药物）将继续有效对抗目前已确定的变异株，包括奥密克戎病毒</blockquote></p><p> The U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p><p><blockquote>美国食品和药物管理局周二表示，正在评估授权的 COVID-19 疫苗对奥密克戎病毒的有效性，并预计在未来几周内获得更多信息。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron<blockquote>Regeneron 的 COVID-19 抗体药物对奥密克戎病毒的疗效可能较差</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron<blockquote>Regeneron 的 COVID-19 抗体药物对奥密克戎病毒的疗效可能较差</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-12-01 11:45</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p><p><blockquote>11月30日（路透社）-<a href=\"https://laohu8.com/S/REGN\">再生元制药</a>该公司周二表示，Inc. 的 COVID-19 抗体药物对奥密克戎病毒的疗效可能较差，这加剧了人们对 Moderna 高层对该公司疫苗提出类似担忧后对现有治疗方法疗效的担忧。</blockquote></p><p> Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p><p><blockquote>Moderna (MRNA.O) 首席执行官的言论再次引发人们对该变种可能会给新生的全球经济复苏带来压力的担忧，导致全球市场暴跌。</blockquote></p><p> Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p><p><blockquote>Regeneron (REGN.O) 表示，根据对 Omicron 个体突变的研究，“疫苗诱导的免疫和单克隆抗体传递的免疫的中和活性可能会降低”，并补充说，该分析包括其 COVID-19 抗体鸡尾酒 REGEN-COV。</blockquote></p><p> The company said it was doing further study to quantify the potential impact using the variant's genetic sequence.</p><p><blockquote>该公司表示，正在进行进一步的研究，以利用该变体的基因序列量化潜在影响。</blockquote></p><p> One of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p><p><blockquote>首席执行官伦·施莱弗 (Len Schleifer) 在接受 CNBC 采访时表示，治疗中使用的一种抗体可能会受到影响，而另一种抗体则不会受到影响。</blockquote></p><p> \"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p><p><blockquote>\"<a href=\"https://laohu8.com/S/JE\">刚刚</a>就像疫苗必须适应一样，我们可能必须不断适应我们的单克隆。”</blockquote></p><p> <a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p><p><blockquote><a href=\"https://laohu8.com/S/LLY\">礼来和</a>Co(LLY.N) 在一份电子邮件声明中告诉路透社，该公司也在努力了解其疗法对奥密克戎的中和活性。</blockquote></p><p> Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p><p><blockquote>再生元股价在早盘交易中下跌约 3%，礼来公司股价下跌 2.5%。</blockquote></p><p> Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p><p><blockquote>竞争对手 Vir Biotechnology Inc(VIR.O) 表示，基于奥密克戎序列，其抗体疗法 sotrovimab 可能会保持对该变异体的效力。</blockquote></p><p> The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p><p><blockquote>它补充说，该公司“正在紧急努力在实验室确认这一点”。</blockquote></p><p> Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p><p><blockquote>吉利德公司 (GILD.O) 表示，相信其静脉注射疗法瑞德西韦（目前唯一获批用于治疗 COVID-19 的抗病毒药物）将继续有效对抗目前已确定的变异株，包括奥密克戎病毒</blockquote></p><p> The U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p><p><blockquote>美国食品和药物管理局周二表示，正在评估授权的 COVID-19 疫苗对奥密克戎病毒的有效性，并预计在未来几周内获得更多信息。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","LLY":"礼来"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1,"symbols_score_info":{"LLY":0.9,"GILD":0.9,"REGN":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1226,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":31,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603962112"}
精彩评论